Clinical trials: Antiplatelet Drug
Coronary Artery Disease, Antiplatelet Drugs
IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
The OPTION2 trial (randomized controlled trial of IndObufen versus asPirin after coronary drug-eluting stent implantaTION in elderly patients with acute coronary syndrome) was designed to compare the 1-year clinical efficacy and…
- Trial name
- OPTION2 (NCT06451198)
- Testing
- Indobufen, Aspirin, Ticagrelor
- Where
- China
- Volunteers
- 2,846 people
- Sponsor
- Shanghai Zhongshan Hospital
Cardiac Event, Coronary Artery Disease
Comparison of Clopidogrel-based Antiplatelet Agent Treatment and Aspirin Plus Low Dose Rivaroxaban Therapy
The study aims to conduct a randomized controlled trial among adults aged 19 years or older who have experienced acute myocardial infarction at least one year prior, or who have other comorbidities such as peripheral arterial…
- Conditions
- Cardiac Event, Coronary Artery Disease, Peripheral Artery Disease, Bleeding
- Trial name
- OACART (NCT07796217)
- Testing
- Aspirin and low-dose rivaroxaban, Clopidogrel with or without aspirin
- Where
- South Korea
- Volunteers
- 2,758 people
- Sponsor
- Seoul National University Bundang Hospital
Cardiovascular Complications, Hemorrhagic Complications
Prospective Cohort of Patient With Coronary Stents Undergoing Non Cardiac Surgery
Non cardiac surgery in patients with coronary stents is complicated with cardiovascular and hemorrhagic events associated with perioperative management of antiplatelet agents.
- Trial name
- RECO (NCT01045850)
- Where
- 53 sites in France
- Volunteers
- 1,312 people
- Sponsor
- University Hospital, Grenoble
Coronary Disease, Cerebral Infarction
The Study on Profile and Genetic Factors of Aspirin Resistance (ProGEAR Study)
The purpose of this study is to determine the clinically meaningful definition and prevalence of aspirin resistance based on data linking aspirin-dependent laboratory tests to recurrent vascular events in cardiovascular patients…
- Conditions
- Coronary Disease, Cerebral Infarction, Ischemic Attack, Transient
- Trial name
- NCT00250380
- Where
- 23 sites in Japan
- Volunteers
- 583 people
- Sponsor
- Ministry of Health, Labour and Welfare, Japan
Coronary Arterioscleroses, Platelet Dysfunction Due to Drugs
The IDEAL-PCI Extended Registry
The purpose of this study is to determine the efficacy and safety of a routine individualized antiplatelet therapy after coronary stent implantation by evaluating "on-treatment" platelet reactivity with Multiple Electrode…
- Trial name
- IDEAL-PCI ext (NCT02974777)
- Testing
- DAPT reduction, DAPT on-target, DAPT intensification
- Where
- Austria
- Sponsor
- Kaiser Franz Josef Hospital
Gastro Intestinal Bleeding, Ischaemic Heart Diseases
Gastrointestinal Bleeding is Blood Loss in the Digestive Tract, Classified as Upper or Lower. Ischemic Heart Disease is Due to Blocked Heart Arteries. Antiplatelet Drugs Help Prevent Heart Attacks But Increase GI Bleeding Risk, Especially When Used Together as Dual Therapy.
Gastrointestinal bleeding is blood loss in the digestive tract, classified as upper or lower. Ischemic heart disease is due to blocked heart arteries.
- Conditions
- Gastro Intestinal Bleeding, Ischaemic Heart Diseases, Antiplatelet Drugs, Antiplatelet Drug-related Gastrointestinal Injury
- Trial name
- NCT07125651
- Volunteers
- 112 people
- Sponsor
- Assiut University
Acute Coronary Syndrome
Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome
Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome
- Trial name
- AReMIS (NCT01952392)
- Where
- France
- Volunteers
- 4,992 people
- Sponsor
- AstraZeneca
Coronary Artery Disease, Stent Thrombosis
Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation
To compare treatment with aspirin alone versus the combined antiplatelet treatment aspirin and clopidogrel after 12 months of combined antiplatelet treatment following drug-eluting stent (DES) implantation.
- Conditions
- Coronary Artery Disease, Stent Thrombosis, Myocardial Ischemia
- Trial name
- OPTIDUAL (NCT00822536)
- Testing
- Aspirin and Clopidogrel, Aspirin
- Where
- France
- Volunteers
- 1,798 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cardiovascular Diseases, Acute Coronary Syndrome
Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study
It is standard treatment to take anti-platelet medication after cardiac catheterization and stent placement to help prevent the formation of blood clots that may cause heart attack or stroke.
- Trial name
- PAPI-2 (NCT01452152)
- Testing
- clopidogrel, prasugrel
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of Maryland, Baltimore
Coronary Artery Disease
Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting
The purpose of this study is to determine whether a 6 month duration of clopidogrel therapy after DES implantation is not inferior to that of a 12 month therapy.
- Trial name
- ISAR-SAFE (NCT00661206)
- Testing
- Clopidogrel
- Where
- 40 sites in United States, Albania and 11 more
- Volunteers
- 4,005 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Cardiovascular Diseases, Acute Coronary Syndrome
Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence
This is a pilot study that was conducted to prove the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers.
- Trial name
- NCT05474053
- Testing
- Ticagrelor 90mg (Brilique), Ticagrelor 90mg (Ticaloguard)
- Where
- Egypt
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Cairo University
Coronary Artery Disease, Coronary Artery Stenosis
Nationwide Cohort Study of Antiplatelet Agents as Primary Prevention
There is no specific recommendation regarding pharmacologic treatment as primary prevention for patients with intermediate coronary artery stenosis whose revascularization was deferred based on negative fractional flow reserve…
- Trial name
- NHIS (NCT06281041)
- Testing
- Antiplatelet Agents
- Where
- South Korea
- Volunteers
- 4,657 people
- Sponsor
- Samsung Medical Center
Platelet Dysfunction Due to Drugs
The Effects of loW Dose tIcagrelor on Platelet Function Testing in Patients With Stable Coronary arTery Disease
This study aims to assess the effects of low dose ticagrelor on platelet function testing in patients with stable coronary artery disease.
- Trial name
- TWIST (NCT04206176)
- Testing
- Ticagrelor
- Where
- Trinidad and Tobago
- Volunteers
- 25 people
- Sponsor
- The University of The West Indies
Cardiovascular Disease (CVD), Stroke
A Genomic Approach for Clopidogrel in Caribbean Hispanics
Clopidogrel is a prescription medicine used to minimize blood clot formation in patients with cardiovascular disease, particularly those undergoing heart catheterization and stroke.
- Conditions
- Cardiovascular Disease (CVD), Stroke, Acute Coronary Syndrome, Peripheral Arterial Disease
- Trial name
- NCT03419325
- Testing
- CYP2C19 test, P2RY12 assay
- Where
- 2 sites in Puerto Rico
- Volunteers
- 150 people
- Sponsor
- University of Puerto Rico
Coronary Artery Disease
Improving Adherence to Post PCI Antiplatelet Therapy in Minority Populations
The purpose of this study is to evaluate if the use of a phone based motivational interviewing among minority populations who received a coronary stent can improve adherence to antiplatelet agents from approximately 51% to 66%…
- Trial name
- NCT01651208
- Testing
- Motivational Interviewing (MINT), Mailed DVD
- Where
- United States
- Volunteers
- 452 people
- Sponsor
- University of Miami
Craniocerebral Trauma, Platelet Aggregation Inhibitors
Correct Timing of Head Imaging in Trauma
The aims of this retrospective and monocentric observational study are: to describe patient characteristics and clinical management of patients with traumatic brain injury taking antiplatelet and/or anticoagulation drugs; to…
- Trial name
- CT-HIT (NCT05306951)
- Testing
- Computed tomography
- Where
- Italy
- Volunteers
- 3,200 people
- Sponsor
- University of Padova
Myocardial Infarction, STEMI
Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics)
Rationale: the use of antiplatelet drugs (i.e. clopidogrel, ticagrelor or prasugrel) is crucial in the treatment of patients undergoing percutaneous coronary intervention (PCI) with stent implantation to prevent atherothrombotic…
- Trial name
- NCT01761786
- Testing
- CYP2C19 genotyping
- Where
- 10 sites in Belgium, Italy and 1 more
- Volunteers
- 2,700 people
- Sponsor
- Vera HM Deneer
Bleeding Complications
Clopidogrel Monotherapy in Patients With High Bleeding Risk
The goal of this research is to show that a shorter duration of two antiplatelet medications (compared to the standard of care) is safe and effective while reducing the risk of bleeding complications.
- Trial name
- NCT05223335
- Testing
- Clopidogrel, Prasugrel, Tricagrelor
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Mayo Clinic
Atrial Fibrillation, Atrial Appendage
AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE
The APPENDAGE study is a phase 4 multicentre randomized opened clinical trial comparing 2 different antithrombotic strategies following left atrial appendage closure (LAAC) in patients with non valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation, Atrial Appendage, Anticoagulants, Stroke
- Trial name
- APPENDAGE (NCT04796714)
- Testing
- Double antiplatelet therapy, Aspirin, Brain MRI
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Bordeaux
Pre-diabetes
Resveratrol and First-degree Relatives of Type 2 Diabetic Patients
The main objective of the study is to investigate if resveratrol supplementation can improve overall and muscle-specific insulin sensitivity in first-degree relatives of type 2 diabetic patients.
- Trial name
- NCT02129595
- Testing
- resveratrol
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Maastricht University Medical Center